August 12, 2025

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapies

View Full Paper

Ask AI

Bookmark

Durable intracranial response achieved after T-DM1 treatment, lasting over 24 months, and well-tolerated with manageable side effects.
Patient previously treated with trastuzumab deruxtecan and tucatinib, highlighting the effectiveness of sequential therapies in HER2-positive metastatic breast cancer.
Case presentation illustrates the potential of T-DM1 for sustained response, emphasizing the need to explore optimal treatment sequencing for brain metastases.
T-DM1 shows clinical relevance in HER2+ MBC with brain metastases where newer agents fail, implying its significant role despite prior treatment failures.

Discussion

No takes yet. Share an insight, caveat, or question.

Case report demonstrates durable intracranial response after T-DM1 in HER2+ MBC, suggesting a viable option after novel therapies fail.

Trevisan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark